View in EDS

PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France.

Saved in:
Bibliographic Details
Title: PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France.
Authors: Massetti, M.1 (AUTHOR), Even, C.2 (AUTHOR), Geoffrois, L.3 (AUTHOR), Farge, G.4 (AUTHOR), Levy Bachelot, L.4 (AUTHOR), Borse, R.5 (AUTHOR), Chirovsky, D.5 (AUTHOR), Durand-Zaleski, I.6 (AUTHOR)
Source: Value in Health. 2020 Supplement 2, Vol. 23, pS436-S436. 1p.
Database: Academic Search Ultimate
Description
ISSN:10983015
DOI:10.1016/j.jval.2020.08.218